其中一个已被考虑的因素是味觉变化,这是一种与药物本身相关的特殊特征。根据其包装说明书,已知以下药物会导致味觉异常:吸入性糖皮质激素(ICS)、ICS与长效β-受体激动剂(LABA)的复方,以及抗胆碱能药物。最近,有报道称某些味觉受体(尤其...
Tariq SM, Thomas EC. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers? Int J Chron Obstruct Pulmon Dis. 2017;12:1877-1882.Tariq SM, Thomas EC. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAM...
The results are promising and favor the LAMA/LABA inhalers, especially in the longer duration trials. Furthermore, there is a clearer picture emerging as to the subgroup of COPD patients who may be able to successfully switch from their current ICS/LABA therapy to these new LAMA/LABA inhaler...
展开更多 Objective To investigate the effects of first-time use of single-inhaler therapy with long-acting beta-2 agonist/long-acting antimuscarinic agent(LABA/LAMA)and inhaled corticosteroids(ICS)/LABA on adherence and exacerbations in patients with chronic obstructive pulmonar...MORE 作者 丛晓飞 ...
triggers, device technique and comorbidities. Therapy should be stepped up as recommended in GINA guidelines in order to attain optimal control, considering individual symptoms, lung function, comorbidities, inhaler technique, adherence and patient preference as important parameters for a personalised choice...
GFF MDI (Bevespi Aerosphere®) is a fixed-dose combination (FDC) of GP (14.4 μg) and the LABA formoterol fumarate dihydrate (FF; 10 μg), delivered by a metered dose inhaler (MDI) using innovative co-suspension delivery technology [[17], [18], [19]]. GFF MDI is the first...
Inhaled bronchodilators including long-acting beta-agonist (LABA) and long-acting muscarinic antagonist (LAMA) play a central role in the treatment of stable chronic obstructive pulmonary disease (COPD). However, it is still unclear whether LABA or LAMA should be used for the initial treatment. ...
10 LAMA/LABA FDCs also improve both transitional dyspnea index and St. George’s Respiratory Questionnaire scores. Furthermore, there is also clear evidence that when the goal of the therapy is to enhance exercise capacity in patients with COPD, LAMA/LABA FDCs consistently meet the putative ...
Since this study did not include measures of adherence, it is not possible to determine whether inadequate symptom control was due to medication-related behaviors among the study population, such as poor adherence or incorrect inhaler administration. A further potential limitation is that the ...
Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.Lancet (London, England. 2016;388(10048):963–973....